KR20210080411A - 스타필로코커스 오레우스(staphylococcus aureus) 류코톡신에 대한 항체 - Google Patents

스타필로코커스 오레우스(staphylococcus aureus) 류코톡신에 대한 항체 Download PDF

Info

Publication number
KR20210080411A
KR20210080411A KR1020217013374A KR20217013374A KR20210080411A KR 20210080411 A KR20210080411 A KR 20210080411A KR 1020217013374 A KR1020217013374 A KR 1020217013374A KR 20217013374 A KR20217013374 A KR 20217013374A KR 20210080411 A KR20210080411 A KR 20210080411A
Authority
KR
South Korea
Prior art keywords
ser
antibody
antigen
val
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217013374A
Other languages
English (en)
Korean (ko)
Inventor
크리스틴 트카지크
브렛 셀만
쿤 두
멜리사 담슈로더
다비드 콜티
안드레아 미놀라
Original Assignee
메디뮨 엘엘씨
후맙스 바이오메드 에스에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디뮨 엘엘씨, 후맙스 바이오메드 에스에이 filed Critical 메디뮨 엘엘씨
Publication of KR20210080411A publication Critical patent/KR20210080411A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020217013374A 2018-10-09 2019-10-08 스타필로코커스 오레우스(staphylococcus aureus) 류코톡신에 대한 항체 Pending KR20210080411A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862743501P 2018-10-09 2018-10-09
US62/743,501 2018-10-09
PCT/US2019/055144 WO2020076790A1 (en) 2018-10-09 2019-10-08 Antibodies directed against staphylococcus aureus leukotoxins

Publications (1)

Publication Number Publication Date
KR20210080411A true KR20210080411A (ko) 2021-06-30

Family

ID=68393067

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217013374A Pending KR20210080411A (ko) 2018-10-09 2019-10-08 스타필로코커스 오레우스(staphylococcus aureus) 류코톡신에 대한 항체

Country Status (11)

Country Link
US (2) US11059884B2 (https=)
EP (1) EP3864040A1 (https=)
JP (1) JP7459075B2 (https=)
KR (1) KR20210080411A (https=)
CN (1) CN113015745B (https=)
AU (1) AU2019359207A1 (https=)
BR (1) BR112021006704A2 (https=)
CA (1) CA3115765A1 (https=)
MX (1) MX2021004114A (https=)
TW (1) TWI895248B (https=)
WO (1) WO2020076790A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX375324B (es) * 2012-11-06 2025-03-06 Medimmune Llc Anticuerpos contra determinantes de la superficie de s. aureus.
TWI902669B (zh) 2018-07-24 2025-11-01 美商麥迪紐有限責任公司 抗金黃色葡萄球菌凝集因子a(clfa)之抗體
MX2021004114A (es) 2018-10-09 2021-07-16 Medimmune Llc Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus.
CN113164602A (zh) 2018-10-09 2021-07-23 免疫医疗有限责任公司 抗金黄色葡萄球菌抗体的组合
CN113811544A (zh) 2019-03-13 2021-12-17 免疫医疗有限责任公司 减少定殖患者中的金黄色葡萄球菌感染
CN113583119B (zh) * 2021-07-07 2023-05-02 西北农林科技大学 抗金黄色葡萄球菌的纳米抗体Nb56、应用及试剂盒
CN113493510A (zh) * 2021-07-07 2021-10-12 上海交通大学 一种牛源抗金黄色葡萄球菌LukD毒力因子的单链抗体及其制备和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
BRPI0807952A2 (pt) 2007-02-20 2014-06-10 Anaptysbio Inc Sistemas de hipermutação somática
CN104119438A (zh) 2009-01-29 2014-10-29 米迪缪尼有限公司 延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用
RU2677140C1 (ru) * 2010-05-05 2019-01-15 Нью-Йорк Юниверсити Лейкоцидины staphylococcus aureus, терапевтические композиции и их применение
EP3470526A3 (en) 2011-02-08 2019-07-17 Medimmune, LLC Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
US9845348B2 (en) 2012-11-06 2017-12-19 Medimmune, Llc Methods of treating S. aureus-associated diseases
MX375324B (es) 2012-11-06 2025-03-06 Medimmune Llc Anticuerpos contra determinantes de la superficie de s. aureus.
EP3057989A1 (en) 2013-10-17 2016-08-24 ARSANIS Biosciences GmbH Cross-reactive staphylococcus aureus antibody sequences
EP3142700B1 (en) 2014-05-16 2021-03-03 Medimmune, LLC Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
MX2017012775A (es) 2015-04-17 2019-04-29 Arsanis Biosciences Gmbh Preparacion combinatoria de anticuerpos anti-staphylococcus aureus.
US20190077851A1 (en) 2015-10-30 2019-03-14 Bruno Francois Methods of using anti-alpha toxin antibody
TWI902669B (zh) 2018-07-24 2025-11-01 美商麥迪紐有限責任公司 抗金黃色葡萄球菌凝集因子a(clfa)之抗體
CN113164602A (zh) 2018-10-09 2021-07-23 免疫医疗有限责任公司 抗金黄色葡萄球菌抗体的组合
MX2021004114A (es) 2018-10-09 2021-07-16 Medimmune Llc Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus.

Also Published As

Publication number Publication date
TWI895248B (zh) 2025-09-01
US11578119B2 (en) 2023-02-14
JP7459075B2 (ja) 2024-04-01
EP3864040A1 (en) 2021-08-18
US20200109190A1 (en) 2020-04-09
CN113015745B (zh) 2025-02-11
WO2020076790A1 (en) 2020-04-16
TW202028232A (zh) 2020-08-01
US20210363229A1 (en) 2021-11-25
BR112021006704A2 (pt) 2021-08-10
CN113015745A (zh) 2021-06-22
AU2019359207A1 (en) 2021-05-20
CA3115765A1 (en) 2020-04-16
JP2022512646A (ja) 2022-02-07
US11059884B2 (en) 2021-07-13
MX2021004114A (es) 2021-07-16

Similar Documents

Publication Publication Date Title
US11578119B2 (en) Antibodies directed against Staphylococcus aureus leukotoxins
US20240352098A1 (en) ANTIBODY DIRECTED AGAINST S. AUREUS CLUMPING FACTOR A (ClfA)
US11168133B2 (en) Combinations of anti-Staphylococcus aureus antibodies
RU2770209C2 (ru) Терапевтические антитела против лиганда cd40
BRPI1014016B1 (pt) anticorpos humanizados para receptor tipo toll 2 e usos dos mesmos.
WO2014028748A1 (en) Interleukin 2 antibodies and antibody complexes
US20250304663A1 (en) Decreasing staphylococcus aureus infections in colonized patients
WO2021186398A1 (en) Anti-klebsiella pneumoniae antibodies and uses thereof
RU2805969C2 (ru) Антитела, направленные против лейкотоксинов staphylococcus aureus
RU2818805C2 (ru) АНТИТЕЛО, НАПРАВЛЕННОЕ ПРОТИВ ФАКТОРА СЛИПАНИЯ А (ClfA) S. aureus
RU2804815C2 (ru) Комбинации антител к staphylococcus aureus

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701